The Claim
In obese male non-human primates, the addition of dual GDF8/activin A blockade to semaglutide treatment over 20 weeks results in progressive increases in lean mass and greater fat loss compared to semaglutide monotherapy, with the combination group exhibiting the most favorable changes in HbA1c, LDL-C, and HDL-C.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In obese male primates, combining a drug that blocks two specific muscle-regulating proteins with semaglutide leads to greater increases in muscle mass and more fat loss than semaglutide alone, along with improved blood sugar and cholesterol levels after 20 weeks of treatment.
See the scientific wording
In obese male non-human primates, adding dual GDF8/activin A blockade to semaglutide treatment over 20 weeks leads to progressive increases in lean mass and greater fat loss compared to semaglutide alone, with the combination group showing the most favorable changes in HbA1c, LDL-C, and HDL-C.
What the research says
1 studyAdding a special muscle-protecting treatment to semaglutide helped obese monkeys keep more muscle and lose more fat than with semaglutide alone, and their blood sugar and cholesterol also improved better.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.